Document is current
Any future updates will be listed below
-
Authors
Janson, Kevin D.
Parkhideh, Siavash
Swain, Joseph W. R.
Weaver, Jessica D.
Hartgerink, Jeffrey D. https://orcid.org/0000-0002-3186-5395
Veiseh, Omid https://orcid.org/0000-0003-1153-8079
-
Funding
Funding for this research was provided by:
JDRF (grant JDRF 3-SRA-2021-1023-S-B, 3-SRA-2025-1640-S-B, 3-SRA-2022-1255-S-B, 3-SRA-2024-1564-S-B, SRA-2023-1398-S-B)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK120459)
United States Department of Defense | Defense Advanced Research Projects Agency (FA8650-21-1-7119, AWD00001596)
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 7 May 2025
First Online: 20 June 2025
Competing interests
: J.D.W. is a co-founder of and holds equity in ImmunoShield Therapeutics. The other authors declare no competing interests.
